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Abstract
Background: The comparative impact of chronic viral monoinfection versus coinfection on inpatient outcomes and
health care utilization is relatively unknown. This study examined trends, inpatient utilization, and hospital outcomes
for patients with HIV, HCV, or HIV/HCV coinfection.
Methods: Data were from the 1996–2010 National Hospital Discharge Surveys. Hospitalizations with primary ICD-9-CM
codes for HIV or HCV were included for HIV and HCV monoinfection, respectfully. Coinfection included both HIV and
HCV codes. Demographic characteristics, select comorbidities, procedural interventions, average hospital length of stay
(LOS), and discharge status were compared by infection status (HIV, HCV, HIV/HCV). Annual disease estimates and
survey weights were used to generate hospitalization rates.
Results: ~6.6 million hospitalizations occurred in patients with HIV (39%), HCV (56%), or HIV/HCV (5%). The hospitalization
rate (hospitalizations per 100 persons with infection) decreased in the HIV group (29.8 in 1996; 5.3 in 2010), decreased in
the HIV/HCV group (2.0 in 1996; 1.5 in 2010), yet increased in the HCV group (0.2 in 1996; 0.9 in 2010). Median LOS from
1996 to 2010 (days, interquartile range) decreased in all groups: HIV, 6 (3–10) to 4 (3–8); HCV, 5 (3–9) to 4 (2–6); HIV/HCV,
6 (4–11) to 4 (2–7). Age-adjusted mortality rates decreased for all three groups. The rate of decline was least pronounced
for those with HCV monoinfection.
Conclusion: Hospitalizations have declined more rapidly for patients with HIV infection (including HIV/HCV coinfection)
than for patients with HCV infection. This growing disparity between HIV and HCV underscores the need to allocate more
resources to HCV care in hopes that similar large-scale improvements can also be accomplished for patients with HCV.
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Background
Human Immunodeficiency Virus (HIV) monoinfection
and hepatitis C virus (HCV) monoinfection have been
the subject of much research over the past two decades;
however, HIV/HCV coinfection is a growing medical
concern in the U.S. [1]. Combination HIV antiretroviral
therapy and combination HCV antiviral therapy have
been recommended since the 1990s, as the respective
treatment regimens greatly reduce patient morbidity
and mortality [2,3]. While HIV antiretroviral and HCV
antiviral therapies are widely recommended for use in
patients with HIV/HCV coinfection [4], these patients
continue to experience poorer health outcomes than their
counterparts with monoinfection. For instance, in the
inpatient setting, patients with coinfection are at increased
risk for accelerated progression of liver disease and
increased rates of morbidity and mortality, as compared
to patients with HIV or HCV monoinfection [5,6].
However, since these combination therapies became
available, few studies have documented how health care
utilization patterns differ for patients with coinfection
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